"A negativedendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial"
PHASE1CompletedINTERVENTIONAL
Enrollment
9
Participants
Timeline
Start Date
May 30, 2017
Primary Completion Date
February 3, 2022
Study Completion Date
February 3, 2022
Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL
tolerogenic dendritic cells (tolDC)
dose-escalation
Trial Locations (1)
2650
Antwerp University Hospital, Edegem
All Listed Sponsors
lead
University Hospital, Antwerp
OTHER
NCT02618902 - "A negativedendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial" | Biotech Hunter | Biotech Hunter